drugset / Trial / NCT03008343
Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer
Phase 1/2
Completed
20 enrolled
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The aim of this study is the safety and efficacy of irreversible electroporation (IRE) plus natural killer (NK) immunotherapy to recurrent liver cancer.
Timeline
- Start
- 2016-12-01
- Primary completion
- 2017-12-01
- Completion
- 2019-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Natural killer | Unknown | 8e+09 cells | Intravenous |